ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 393,76
0,00%
Dow Jones
42 392,27
-0,36%
DAX
20 004,15
0,00%
Brent Oil
75,845
-0,01%
Bitcoin
96 384,81
-0,53%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. XOMA Royalty Corporation (XOMAP) Cours

XOMA Royalty Corporation

XOMA Royalty Corporation (XOMAP)

NASDAQ
25,88
0,00
(0,00%)
Fermé 03 Janvier 10:00PM
Retardé de 15 minutes
0,00
0,00
(0,00%)
Après les heures de négociation: -
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
25,88
Prix Achat
25,35
Prix Vente
28,80
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
304,937M
Clôture Veille
25,88
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
11 782 723
Rendement du Dividende
8.33%
Ratio Cours sur Bénéfices
-7,51
Bénéfice par action (BPA)
-3,47
Chiffre d'affairess
4,76M
Bénéfice net
-40,83M

À propos de XOMA Royalty Corporation

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.xoma.com
Siège social
Wilmington, Delaware, USA
Fondé
-
XOMA Royalty Corporation est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker XOMAP. Le dernier cours de clôture d'XOMA Royalty était de US$25,88. Au cours de la dernière année, les actions de XOMA Royalty ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

XOMA Royalty compte actuellement 11 782 723 actions en circulation. La capitalisation boursière d'XOMA Royalty est de US$304,94 million. XOMA Royalty a un ratio cours/bénéfice (ratio PE) de -7.51.

XOMAP Dernières nouvelles

Plus de nouvelles

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of...

19 Décembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

02 Décembre 2024
Edgar (US Regulatory)

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and...

02 Décembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

14 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

14 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s...

07 Novembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

22 Octobre 2024
Edgar (US Regulatory)

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating...

22 Octobre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000PR
40000000PR
120000000PR
260000000PR
520000000PR
1560000000PR
2600000000PR

XOMAP - Frequently Asked Questions (FAQ)

What is the current XOMA Royalty share price?
The current share price of XOMA Royalty is US$ 25,88
How many XOMA Royalty shares are in issue?
XOMA Royalty has 11 782 723 shares in issue
What is the market cap of XOMA Royalty?
The market capitalisation of XOMA Royalty is USD 304,94M
What is the 1 year trading range for XOMA Royalty share price?
XOMA Royalty has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of XOMA Royalty?
The price to earnings ratio of XOMA Royalty is -7,51
What is the cash to sales ratio of XOMA Royalty?
The cash to sales ratio of XOMA Royalty is 64,41
What is the reporting currency for XOMA Royalty?
XOMA Royalty reports financial results in USD
What is the latest annual turnover for XOMA Royalty?
The latest annual turnover of XOMA Royalty is USD 4,76M
What is the latest annual profit for XOMA Royalty?
The latest annual profit of XOMA Royalty is USD -40,83M
What is the registered address of XOMA Royalty?
The registered address for XOMA Royalty is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the XOMA Royalty website address?
The website address for XOMA Royalty is www.xoma.com
Which industry sector does XOMA Royalty operate in?
XOMA Royalty operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ONCBeiGene Ltd
 184,21
(731,65%)
132,21k
RAINRain Enhancement Technologies Holdco Inc
 6,75
(457,85%)
211,35k
NITON2OFF Inc
US$ 1,07
(331,45%)
603,87M
CTCXCarmell Corporation
US$ 0,6991
(150,48%)
314,15M
TXMDTherapeuticsMD Inc
US$ 1,58
(83,72%)
7,41M
NMRANeumora Therapeutics Inc
US$ 1,965
(-81,46%)
44,29M
THCHTH International Limited
US$ 0,71
(-80,00%)
46,39k
MARXMars Acquisition Corporation
US$ 2,47
(-73,58%)
1,19M
SISIShineco Inc
US$ 2,07
(-54,30%)
1,73M
MARXUMars Acquisition Corporation
US$ 6,23
(-40,10%)
66,1k
NITON2OFF Inc
US$ 1,07
(331,45%)
603,55M
MBIOMustang Bio Inc
US$ 0,2093
(18,25%)
310,88M
CTCXCarmell Corporation
US$ 0,6991
(150,48%)
309,04M
CGBSCrown LNG Holdings Ltd
US$ 0,6749
(68,68%)
278,33M
SVMHSRIVARU Holding Ltd
US$ 0,0599
(42,28%)
275,21M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
XOMAP
XOMA Royalty
AMEX
GPUS-D
Hyperscale Data
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés